Get the Stockscreener App
167.47
2.05%
-3.5301
Jazz Pharmaceuticals Plc stock is traded at $167.47, with a volume of 213.42K.
It is down -2.05% in the last 24 hours and down -1.17% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$171.00
Open:
$170.56
24h Volume:
213.42K
Relative Volume:
0.19
Market Cap:
$10.17B
Revenue:
$4.09B
Net Income/Loss:
$-404.84M
P/E Ratio:
-24.82
EPS:
-6.7469
Net Cash Flow:
$1.24B
1W Performance:
-1.13%
1M Performance:
-1.17%
6M Performance:
+42.74%
1Y Performance:
+36.75%
1-Day Range:
$167.36
$171.51
1-Week Range:
$165.01
$171.70
52-Week Range:
$95.49
$182.99
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
167.39 | 10.39B | 4.09B | -404.84M | 1.24B | -6.7469 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.89 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.65 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.52 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Downgrade | UBS | Buy → Neutral |
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Dip Buying: Why is Jazz Pharmaceuticals plc stock going upEarnings Risk Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Acute Myeloid Leukemia Market Forecast to 2034: 7MM Opportunity, Strong CAGR, 43,500 Annual Cases, and Pipeline-Driven Growth | DelveInsight - Barchart.com
Lmcg Investments LLC Trims Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Aug Mood: Will Jazz Pharmaceuticals plc benefit from green energy policiesTrade Exit Report & Community Consensus Stock Picks - baoquankhu1.vn
Jazz Pharmaceuticals (JAZZ) Is Up 5.1% After Monetizing FDA Voucher And Expanding Oncology Collaboration - Yahoo Finance
Is Jazz (JAZZ) Quietly Recasting Its Oncology Strategy Through HER2 Partnerships And Voucher Monetization? - simplywall.st
New York State Teachers Retirement System Sells 9,223 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug - MSN
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Momentum - simplywall.st
JPM26: Jazz sells PRV for $200m, targets deals in 2026 - Pharmaceutical Technology
JAZZJazz Pharmaceuticals Plc Latest Stock News & Market Updates - Stock Titan
Jazz Sells Priority Review Voucher for $200M as Program’s Renewal Languishes in Senate - BioSpace
Jazz Pharmaceuticals stock rating reiterated at Outperform by RBC Capital - Investing.com Nigeria
Jazz Pharmaceuticals Soars with Promising HERIZON-GEA-01 Results - timothysykes.com
Jazz sells priority review voucher for $200 million - First Word Pharma
JAZZ: Sharpened rare disease focus, record growth, and pivotal zanidatamab results drive future milestones - TradingView — Track All Markets
JAZZ: Rare disease focus, record revenues, and zanidatamab's breakthrough in GEA drive future growth - TradingView — Track All Markets
JAZZ: Refined rare disease focus, strong 2025 results, and new launches drive future growth - TradingView — Track All Markets
Baird reiterates Underperform rating on Jazz Pharmaceuticals stock at $209 By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals PLC $JAZZ Holdings Lessened by Polaris Capital Management LLC - MarketBeat
Jazz Pharmaceuticals price target raised to $235 from $210 at Needham - Yahoo Finance
Jazz Pharmaceuticals stock price target raised to $263 from $247 at BofA - Investing.com Nigeria
Jazz Pharmaceuticals stock price target raised to $230 by Truist Securities - Investing.com Nigeria
Jazz Pharmaceuticals (JAZZ): Truist Securities Boosts Price Targ - GuruFocus
Truist Financial Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price - MarketBeat
Jazz Pharmaceuticals plcExpects to meet 2025 revenue guidanceSEC filing - marketscreener.com
Jazz Pharmaceuticals PLCExpects To Meet 2025 Revenue GuidanceSEC Filing - TradingView — Track All Markets
Jazz Pharmaceuticals stock price target raised to $235 by Needham - Investing.com Nigeria
Boehringer and Jazz to test HER2-positive breast cancer combo therapy - Investing.com UK
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer - The Manila Times
What Analysts Are Saying About Jazz Pharmaceuticals Stock - Benzinga
Needham Raises Price Target for Jazz Pharmaceuticals (JAZZ) to $235 | JAZZ Stock News - GuruFocus
Is Jazz Pharmaceuticals (JAZZ) Offering Value After Recent Pullback And 32.7% One Year Gain - Yahoo Finance
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Weakness - Yahoo Finance
Is Jazz Pharmaceuticals (JAZZ) Still Attractive After 33% Share Price Gain This Year? - simplywall.st
Jazz Pharmaceuticals plc (JAZZ) Advances Rare Cancer Portfolio with First CNS Glioma Therapy Approval - MSN
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates - sharewise.com
Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology (NASDAQ:JAZZ) - Seeking Alpha
Jazz Pharmaceuticals touts Phase 3 zanidatamab OS win in HER2+ GEA, eyes FDA sBLA in H1 - MarketBeat
Jazz Pharmaceuticals (JAZZ) Is Down 5.7% After Strong Ziihera Phase 3 DataHas The Bull Case Changed? - simplywall.st
Lecap Asset Management Ltd. Buys Shares of 6,319 Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by MassMutual Private Wealth & Trust FSB - MarketBeat
Robeco Institutional Asset Management B.V. Cuts Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Why Jazz Pharmaceuticals plc stock remains resilient2025 Earnings Impact & Daily Chart Pattern Signals - ulpravda.ru
What sentiment indicators say about Jazz Pharmaceuticals plc stockJuly 2025 WrapUp & Technical Confirmation Trade Alerts - ulpravda.ru
Jazz pharmaceuticals appoints Thomas Riga as chief business officer By Investing.com - Investing.com South Africa
Jazz pharmaceuticals appoints Thomas Riga as chief business officer - Investing.com
Jazz Pharmaceuticals names Thomas Riga as Chief Business Officer - StreetInsider
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer - marketscreener.com
Should I hold or sell Jazz Pharmaceuticals plc stock in 2025Weekly Trend Summary & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Positive Ziihera Phase 3 Gastroesophageal Cancer Results - simplywall.st
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):